XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.
Rhea-AI Summary
XOMA Royalty (NASDAQ: XOMA) announced it completed its tender offer and acquisition of Generation Bio (NASDAQ: GBIO). Generation Bio stockholders received $4.2913 per share in cash plus one non-tradeable contingent value right (CVR). Approximately 4,722,533 shares (~70%) were validly tendered. Following the tender, XRA 7 Corp. merged into Generation Bio, which became a wholly owned subsidiary of XOMA Royalty. Trading in Generation Bio common stock ceased on Nasdaq after market close on February 6, 2026, and the companies intend to delist and deregister those shares.
Positive
- Acquisition completed: Generation Bio is now a wholly owned subsidiary of XOMA Royalty
- Majority acceptance: 4,722,533 shares tendered, representing approximately 70% of outstanding shares
- All tender conditions satisfied and XOMA Royalty accepted and will promptly pay for validly tendered shares
- Outstanding shares not tendered converted into right to receive the same Offer Price
Negative
- Contingent value right (CVR) issued is non-tradeable, limiting immediate liquidity for that component
- Generation Bio common stock ceased trading and will be delisted and deregistered, reducing public liquidity
News Market Reaction
On the day this news was published, XOMAP gained 0.39%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
XOMA slipped 0.24% while only one peer (ARCT) appeared in momentum scans moving down; other close peers in biotechnology showed gains, pointing to a company-specific move tied to XOMA’s news flow.
Previous Acquisition Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 05 | Acquisition closing | Positive | -3.3% | Completed acquisition of Mural Oncology via Irish court-sanctioned scheme of arrangement. |
| Nov 21 | Acquisition closing | Positive | -0.3% | Closed acquisition of LAVA Therapeutics with cash plus CVR structure and reorganization. |
| Oct 02 | Tender extension | Positive | +0.5% | Extended tender offer for LAVA, retaining cash plus non-transferable CVR deal terms. |
| Aug 20 | Acquisition agreement | Positive | +1.3% | Announced agreement for XRA 5 Corp. to acquire Mural Oncology in all-cash deal. |
| Aug 04 | Acquisition agreement | Positive | +10.0% | Entered definitive agreement to acquire LAVA with cash consideration plus CVR economics. |
Acquisition-related headlines for XOMA have more often seen modest positive alignment, but there have also been instances where the stock traded lower despite seemingly constructive deal announcements.
Over recent months, XOMA has repeatedly used acquisitions to expand its royalty-aggregator model, announcing agreements and closings for LAVA Therapeutics and Mural Oncology. Prior acquisition news on Aug 4, 2025 and Aug 20, 2025 focused on structured cash-plus-CVR consideration and defined premiums. Later updates on Nov 21, 2025 and Dec 5, 2025 confirmed transaction closings and delistings. Today’s Generation Bio acquisition closing follows this established pattern of cash plus CVR structures and subsequent take-private outcomes.
Historical Comparison
In recent acquisition announcements, XOMA shares moved an average of 1.63%, with a mix of modest gains and occasional selloffs around deal agreements and closings.
XOMA has progressed from signing LAVA and Mural deals to extending tender periods and ultimately closing both acquisitions, consistently using cash plus CVR-style consideration and follow-on delistings.
Market Pulse Summary
This announcement confirms completion of XOMA’s tender offer and merger to acquire Generation Bio, using a familiar mix of cash plus a contingent value right and subsequent delisting. It continues a pattern seen in prior LAVA and Mural transactions, reinforcing XOMA’s acquisition-led royalty aggregation strategy. Investors tracking this theme may watch how acquired programs contribute over time relative to earlier deals that historically moved shares by an average of 1.63% around similar news.
Key Terms
contingent value right financial
tender offer financial
withdrawal rights financial
AI-generated analysis. Not financial advice.
Generation Bio Stockholders Received
EMERYVILLE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company successfully completed its previously announced tender offer to acquire all outstanding shares of Generation Bio Co. (NASDAQ: GBIO) (“Generation Bio”) common stock for a price per share of
The tender offer and related withdrawal rights expired one minute after 11:59 p.m. Eastern Time on Friday, February 6, 2026 (the “Expiration Date”). As of the Expiration Date, a total of 4,722,533 shares of Generation Bio common stock were validly tendered, and not validly withdrawn, representing approximately
Following the closing of the tender offer, a subsidiary of the Company, XRA 7 Corp., merged with and into Generation Bio (the “Merger”), and all shares of Generation Bio common stock that had not been validly tendered and irrevocably accepted for purchase were converted into the right to receive the Offer Price without interest. As a result of the Merger, Generation Bio became a wholly owned subsidiary of XOMA Royalty. Following the closing of trading on The Nasdaq Stock Market LLC (“Nasdaq”) on February 6, all shares of Generation Bio common stock ceased trading on Nasdaq, and the Company and Generation Bio intend promptly to cause such shares to be delisted from Nasdaq and deregistered under the Securities Exchange Act of 1934, as amended.
Advisors
XOMA Royalty was represented by Gibson, Dunn & Crutcher LLP. TD Cowen served as financial advisor, and Wilmer Cutler Pickering Hale and Dorr LLP served as legal counsel to Generation Bio.
About XOMA Royalty Corporation
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. XOMA Royalty has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about XOMA Royalty and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.
Forward-Looking Statements/Explanatory Notes
Certain statements contained in this press release are forward-looking statements, including statements regarding the payment and expected timing of payment of the tender offer, the delisting and deregistration of Generation Bio common stock, the ability of XOMA Royalty to monetize Generation Bio’s delivery platform for the benefit of XOMA Royalty and Generation Bio stockholders, and the ability to achieve any dispositions within the disposition period under the CVR Agreement. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “approximately,” “look to,” “plan,” “expect,” “may,” “will,” “could” or “should,” the negative of these terms or similar expressions. These forward-looking statements are not a guarantee of XOMA Royalty’s performance, and you should not place undue reliance on such statements. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks including the risk that XOMA Royalty does not achieve anticipated net cash after winding down Generation Bio’s operations and concluding remaining activities, and the risk that XOMA Royalty is unable to develop or otherwise enter into dispositions related to the Generation Bio programs. Other potential risks to XOMA Royalty meeting these expectations are described in more detail in XOMA Royalty's most recent filing on Form 10-Q and in other filings with the Securities and Exchange Commission. Any forward-looking statement in this press release represents XOMA Royalty's beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA Royalty disclaims any obligation to update any forward-looking statement, except as required by applicable law.
EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.
| XOMA Royalty Investor Contact Juliane Snowden XOMA Royalty Corporation +1-646-468-9754 juilane.snowden@xoma.com | XOMA Royalty Media Contact Kathy Vincent KV Consulting & Management kathy@kathyvincent.com |
FAQ
What did XOMA (NASDAQ: XOMA) announce about the acquisition of Generation Bio on February 9, 2026?
How much did Generation Bio (NASDAQ: GBIO) stockholders receive per share in the XOMA offer?
How many Generation Bio shares were tendered in XOMA's offer and what percentage did that represent?
What happened to Generation Bio shares that were not tendered to XOMA (NASDAQ: XOMA)?
Will Generation Bio (NASDAQ: GBIO) remain listed on Nasdaq after the acquisition by XOMA?
